ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. Event: Canaccord Genuity 45th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 12:30pm ET/9:30am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com ...

For the quarter ended June 2025, Penumbra (PEN) reported revenue of $339.46 million, up 13.4% over the same period last year. EPS came in at $0.86, compared to $0.64 in the year-ago quarter.The reported revenue represents a surprise of +3.54% over the Zacks Consensus Estimate of $327.85 million. With the consensus EPS estimate being $0.81, the EPS surprise was +6.17%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024. U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% c ...

Company Overview - Inari Medical, now part of Stryker, has launched the next-generation InThrill Thrombectomy System, which is the first and only purpose-built small vessel and arteriovenous (AV) access thrombectomy system designed for fast, full luminal clot removal [1][2][3]. Product Features - The InThrill Thrombectomy System is an 8 French over-the-wire system that includes the InThrill thrombectomy catheter and sheath, optimized to set a new standard for AV access and small vessel thrombectomy [3]. - Key features of the InThrill system include increased radial force for improved luminal wall apposition, an offset single open mouth for optimized clot capture, internal struts for even clot distribution, and a redesigned backend for enhanced ergonomics [9]. Clinical Application - The system is indicated for the non-surgical removal of thrombi and emboli from blood vessels, including arteriovenous fistulae and grafts for dialysis access, as well as for the injection, infusion, and aspiration of contrast media and other fluids [7]. Market Impact - The launch of the InThrill Thrombectomy System reflects Stryker's commitment to addressing real-world challenges in vascular care, enhancing collaboration with physicians in the vascular space [4]. - Stryker, as a global leader in medical technologies, impacts over 150 million patients annually through innovative products and services [4]. Acquisition Context - Stryker acquired Inari Medical on February 19, 2025, with the aim of transforming the treatment of patients suffering from venous and other diseases [5].

Core Viewpoint - Penumbra, Inc. will host a conference call to discuss its financial results for the second quarter of 2025 on July 29, 2025, at 4:30 PM Eastern Time, with a press release to follow after market close on the same day [1]. Group 1: Conference Call Details - The conference call can be accessed via phone at (888) 596-4144 with conference ID 6572573, or through a webcast available on the company's website [2]. - The webcast will remain accessible on the company's website for at least two weeks after the call [2]. Group 2: Company Overview - Penumbra, Inc. is recognized as the world's leading thrombectomy company, focusing on innovative technologies for medical conditions such as ischemic stroke and venous thromboembolism [3]. - The company's portfolio includes computer-assisted vacuum thrombectomy (CAVT), aimed at efficiently removing blood clots from various parts of the body [3]. - Penumbra supports healthcare providers in over 100 countries, striving to enhance patient outcomes and quality of life [3].

Core Insights - Penumbra, Inc. has completed enrollment in the STORM-PE clinical trial, which is a pioneering study comparing computer-assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone for treating acute intermediate-high risk pulmonary embolism [1][2] - The trial enrolled 100 patients and aims to provide high-quality evidence on the effectiveness of CAVT in improving right heart function and clinical outcomes in patients with pulmonary embolism [1][2][4] - Pulmonary embolism is a significant health concern, with an estimated 900,000 symptomatic cases occurring annually in the U.S., and a mortality rate of 10-30% within one month of diagnosis [3] Company Overview - Penumbra, Inc. is recognized as the world's leading thrombectomy company, focusing on innovative technologies for medical conditions such as ischemic stroke and venous thromboembolism [6] - The company's Lightning Flash portfolio features advanced mechanical thrombectomy systems designed to remove blood clots efficiently, utilizing dual clot detection algorithms and a specialized catheter design [4][6] - Penumbra operates in over 100 countries, aiming to enhance patient outcomes and quality of life through its innovative medical solutions [6]

Core Insights - Penumbra, Inc. is scheduled to present at multiple investor conferences in June 2025, showcasing its commitment to engaging with investors and stakeholders [1][2]. Group 1: Upcoming Events - The company will present at the William Blair 45th Annual Growth Stock Conference on June 3, 2025, at 3:00 PM ET [2]. - The Jefferies Global Healthcare Conference is scheduled for June 4, 2025, at 9:55 AM ET [2]. - The Truist Securities MedTech Conference will take place on June 17, 2025, at 10:00 AM ET [2]. Group 2: Company Overview - Penumbra, Inc. is recognized as the world's leading thrombectomy company, focusing on innovative technologies for medical conditions like ischemic stroke and venous thromboembolism [3]. - The company's portfolio includes computer-assisted vacuum thrombectomy (CAVT), aimed at efficiently removing blood clots [3]. - Penumbra operates in over 100 countries, supporting healthcare providers to enhance patient outcomes and quality of life [3].

Core Viewpoint - Surmodics, Inc. reported a wider-than-expected adjusted loss per share and lower-than-expected revenues for the second quarter of fiscal 2025, indicating challenges in its Medical Device segment and overall financial performance [1][14]. Revenue Performance - Surmodics generated revenues of $28.1 million in the fiscal second quarter, a decrease of 12.1% year over year, missing the Zacks Consensus Estimate by 8.7% [2]. - Total revenues included $0.3 million from SurVeil drug-coated balloon (DCB) license fees, down from $1.1 million in the same quarter of the previous year, attributed to lower expenses related to the TRANSCEND clinical trial [3]. - Product sales were $14.9 million, down 17.2% from the prior-year quarter, and royalties and license fees totaled $9.9 million, down 13.2% [7]. Segment Analysis - The Medical Device segment reported sales of $20.7 million, a decline of 16.6% year over year, with revenues excluding SurVeil DCB license fees decreasing 14% [5]. - In Vitro Diagnostics (IVD) sales improved by 3.4% year over year to $7.4 million, driven by favorable order timing, although this was offset by a decline in microarray slide/surface revenues [6]. Margin and Expenses - Gross profit decreased by 18.5% year over year to $20.3 million, with gross margin contracting 566 basis points to 72.1% [9]. - Selling, general & administrative expenses increased by 14.9% year over year to $15 million, while research and development expenses declined by 18.2% to $8.4 million [9]. Financial Position - Surmodics ended the second quarter with cash and cash equivalents of $29.2 million, a slight decrease from $30.1 million at the end of the previous quarter [11]. - Total long-term debt was $29.63 million, marginally up from $29.59 million in the prior quarter [11]. Fiscal Guidance - The company expects total revenues for fiscal 2025 to be in the range of $114 million to $117 million, reflecting a decrease of 10-7% compared to fiscal 2024 [12]. - Surmodics anticipates a decrease of $3.6 million in SurVeil DCB license fee revenues and a $7 million decrease in SurVeil DCB product revenues for fiscal 2025 [13]. Market Reaction - Shares of Surmodics fell nearly 9.4% at the end of the trading session following the earnings report [4].

Company Overview - Penumbra, Inc. is the world's leading thrombectomy company focused on developing innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia [2] - The company's portfolio includes computer assisted vacuum thrombectomy (CAVT), aimed at removing blood clots efficiently and safely [2] - Penumbra supports healthcare providers in over 100 countries, working to improve patient outcomes and quality of life [2] Upcoming Event - Penumbra's management team is scheduled to present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 6:00 PM ET [1] - A webcast of the presentation will be available on the company's website for at least two weeks following the event [1]

Core Insights - Penumbra Inc reported better-than-expected first-quarter 2025 earnings and reaffirmed its 2025 forecast, leading to an increase in stock price [1][5] Financial Performance - Revenue from global thrombectomy products reached $226.5 million in Q1 2025, marking a 20.7% increase, or 21.2% in constant currency [1] - U.S. thrombectomy revenue was $187.9 million, reflecting a year-over-year increase of 25.0% [1] - Revenue from global embolization and access products grew to $97.6 million, a 7.3% increase, or 8.1% in constant currency [2] - U.S. embolization and access products revenue increased by 16.2% to $68.97 million [2] - Operating income was $40.4 million, with Q1 net income at $39.2 million and adjusted EBITDA of $59.6 million, resulting in margins of 12.1% and 18.4% respectively [2][6] - Total sales for the quarter were $324.1 million, up 16.3% year over year, exceeding the consensus estimate of $315.66 million [6] Guidance and Outlook - Penumbra reaffirmed its fiscal year 2025 sales guidance of $1.34 billion to $1.36 billion, aligning with the consensus of $1.35 billion [3] - The company increased its guidance for U.S. thrombectomy franchise growth to 20% to 21% year over year, up from the previous estimate of 19% to 20% [7] - Guidance for gross margin expansion is set at a minimum of 100 basis points in 2025, targeting over 67% for the full year, and operating margin expansion to 13%-14% of revenue for 2025 [7] Analyst Insights - William Blair noted that Penumbra is well-insulated from tariff impacts due to its domestic manufacturing and sourcing of 75% of raw materials in the U.S. [4] - Multiple analysts maintained positive ratings on Penumbra, with price targets raised: Stifel from $301 to $318, Truist from $315 to $330, Wells Fargo from $305 to $315, Baird from $316 to $325, and UBS from $320 to $330 [8]